Last updated: February 24, 2026
What is NDC 52427-0430?
NDC 52427-0430 identifies a specific pharmaceutical product. Based on the National Drug Code (NDC) system, it belongs to a drug marketed in the United States. According to available databases, this NDC corresponds to Chantix (varenicline), a prescription medication used to aid smoking cessation.
Market Landscape
Market Size and Revenue
- The global smoking cessation market was valued at approximately $1.1 billion in 2021.
- It is projected to grow annually at 6-8% through 2028, driven by increased awareness and regulatory efforts around tobacco control.
- The U.S. market represents roughly 70-80% of the total, with local sales approximating $750 million in 2022.
Competitive Environment
- Key competitors include bupropion (Zyban), nicotine replacement therapies, and newer molecular agents.
- Chantix maintains a significant market share: around 50% of prescriptions for smoking cessation drugs in the U.S.
- Patent exclusivity expired in 2022, leading to increased generic competition.
Regulatory and Patent Status
- Original patents for Chantix expired in April 2022.
- Several generics approved for market entry since 2022, notably Mylan's varenicline tablets.
- White label and branded generics now share market volume, exerting downward pressure on prices.
Market Adoption
- Physicians prefer Chantix due to higher efficacy and patient adherence.
- Patient awareness remains high; however, safety concerns have influenced prescribing patterns.
- Insurance coverage remains a support factor, with most plans covering Chantix with minimal copayments.
Pricing Analysis
Historical Pricing Data
| Year |
Brand Name (Chantix) |
Average Wholesale Price (AWP) |
Estimated Retail Price (ERP) |
| 2021 |
Chantix 0.5 mg, 30 tablets |
$272 |
$330 |
| 2022 |
Chantix 1 mg, 30 tablets |
$285 |
$350 |
| 2023 |
Generic equivalents available |
$150–$200 |
$180–$220 |
Current Price Trends
- Generic versions now retail at 40-50% lower than the branded product.
- Brand pricing stabilizes around 10-15% premium over generics, justified by brand recognition and perceived efficacy.
- Pharmacies increasingly favor generics for margin and market competitiveness.
Price Projections (Next 3-5 Years)
| Year |
Estimated Brand Price (ERP) |
Estimated Generic Price (ERP) |
| 2024 |
$330–$360 |
$180–$220 |
| 2025 |
$320–$340 |
$170–$210 |
| 2026 |
$310–$330 |
$160–$200 |
Discounting factors: Improved generic competition, increased use of biosimilars, and potential regulatory pressures may reduce prices further by 5-10% annually.
Market Entry and Expansion Opportunities
- Biosimilar or novel formulations could alter the competitive landscape.
- Expansion into emerging markets could offset U.S. pricing erosion.
- Combination therapies or extended-release formulations may command premium pricing.
Key Takeaways
- NDC 52427-0430 corresponds to Chantix (varenicline), a significant player in the smoking cessation market.
- The expiration of patents in 2022 led to increased generic competition, influencing pricing downward.
- The market is forecast to see stabilized branded prices at around $330–$360 annually, with generics priced between $180–$220.
- Revenue will depend on physician prescribing habits, insurance coverage, and regional competition.
- Future pricing will likely trend downward, impacted by biosimilars, regulatory changes, and new entrants.
FAQs
Q1: What factors most influence the price of Chantix (NDC 52427-0430)?
Prescription volume, generic competition, insurance reimbursement policies, and regulatory environments.
Q2: How has the patent expiration affected market dynamics?
Patent expiration increased generic entry, leading to price reductions, increased accessibility, and competition for market share.
Q3: Are biosimilars relevant for this drug?
No. Varenicline is a small-molecule drug, so biosimilars do not apply; generics are the primary alternative.
Q4: What growth opportunities exist outside the U.S.?
Emerging markets with less generic penetration and lower regulatory barriers present expansion possibilities.
Q5: How might regulatory or policy changes impact prices?
Potential regulatory pressures for price controls, safety monitoring, or new approvals could influence pricing and market share.
References
[1] MarketWatch. (2022). Smoking cessation drugs market size, share, growth analysis.
[2] IQVIA. (2023). U.S. prescription drug market data.
[3] FDA. (2022). Patent expiration dates and generic approvals.
[4] Statista. (2023). Global smoking cessation market forecast.
[5] RxMed. (2023). Average wholesale prices for smoking cessation drugs.
